文献速递术前评估与围术期医学

丙泊酚与瑞芬太尼靶控输注中深度镇静的不良事件及危险因素:2937例回顾性队列研究

Moderate-to-Deep Sedation Using Target-Controlled Infusions of Propofol and Remifentanil: Adverse Events and Risk Factors: A Retrospective Cohort Study of 2937 Procedures.
PubMed 文献 · Anesth Analg · 2020-01-01

未发生死亡、心肺复苏或非计划ICU入住等灾难性事件,32例发生严重镇静相关事件,以严重低氧饱和度(0.6%)和严重高血压(0.2%)最常见;显著低血压(8.8%)和显著低氧饱和度(1.6%)为最常见潜在不良健康后果事件,无患者遗留持续健康损害。

要点

  • 丙泊酚与瑞芬太尼TCI中深度镇静灾难性事件发生率低。
  • 严重事件以严重低氧饱和度(0.6%)和严重高血压(0.2%)为主。
  • 高BMI为低氧饱和度危险因素,高龄和低BMI为低血压危险因素,手术时间长为两者共同危险因素。

核心结论

  • 丙泊酚与瑞芬太尼靶控输注中深度镇静的灾难性和严重事件发生率低。

主要发现

  • 无患者发生死亡、需心肺复苏或非计划ICU入住等灾难性事件。
  • 32例发生32次严重镇静相关事件,其中严重低氧饱和度发生率为0.6%(95%CI 0.4-0.9),严重高血压发生率为0.2%(95%CI 0.04-0.37)。
  • 显著低血压发生率为8.8%(95%CI 7.73-9.77),显著低氧饱和度发生率为1.6%(95%CI 1.12-2.02),为最常见的潜在不良健康后果事件。
  • 无患者遗留持续健康损害。
  • 丙泊酚平均及最大目标效应室浓度(Cet)分别为2.6±0.83和3.3±1.09 µg·mL,瑞芬太尼分别为0.84±0.18和0.99±0.22 ng·mL。

临床怎么用

  • 该服务模型下丙泊酚与瑞芬太尼TCI中深度镇静严重事件少见,可支持由麻醉科培训护士按方案实施。
  • 应关注高BMI患者的低氧饱和度风险以及高龄、低BMI患者的低血压风险。
  • 手术时间较长时需同时警惕低氧饱和度和低血压的发生。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the University Medical Center Groningen in Groningen, the Netherlands, moderate-to-deep sedation is provided by nursing staff trained and supervised by the anesthesia department using protocol-based target-controlled infusions (TCIs) of propofol and remifentanil. The aim of this retrospective cohort study was to investigate the incidence of events with potential adverse health consequences within this service model and the risk factors for the occurrence of these events. METHODS: We retrospectively interrogated a database containing the computerized anesthetic records of 2937 procedures where moderate-to-deep sedation was provided using TCI administration of propofol and remifentanil between May 2014 and October 2017. The primary outcome measures were the incidence of sedation-related events with potential adverse health consequences and risk factors for the occurrence of such events. The events under investigation were unplanned intensive care unit (ICU) admission, need for cardiopulmonary resuscitation (CPR), death on the day of the procedure due to sedation-related events, cardiovascular events (arrhythmias, hypertension, and hypotension), pulmonary events (aspiration, desaturation, unplanned tracheal intubation), anaphylactic or allergic reactions, and the termination of the procedure due to sedation-related events. Cardiovascular and pulmonary events were classified as severe, significant, or moderate. Events were identified by using computer algorithms to search the computerized records from all included procedures. RESULTS: Data from 2937 procedures were analyzed. No patients suffered catastrophic events (death, need for CPR, or unplanned ICU admission). Thirty-two severe sedation-related events occurred in 32 procedures. Severe desaturation (0.6%; 95% confidence interval [CI], 0.4-0.9) and severe hypertension (0.2%; 95% CI, 0.04-0.37) were the most common severe events. Significant hypotension (8.8%; 95% CI, 7.73-9.77) and significant desaturation (1.6%; 95% CI, 1.12-2.02) were found to be the most common events with potential adverse health consequences. No patient suffered lasting health consequences. Average mean and maximum targeted effect-site concentrations (Cet) for propofol were 2.6 ± 0.83 and 3.3 ± 1.09 µg·mL, respectively, and for remifentanil 0.84 ± 0.18 and 0.99 ± 0.22 ng·mL, respectively. Maximum Cets of propofol were lower among patients with higher body mass index (BMI) and were higher among patients of younger age. Higher BMI was a risk factor for desaturation. Increased age and lower BMI were risk factors for hypotension. Longer procedure time was a risk factor for both desaturation and hypotension. CONCLUSIONS: Moderate-to-deep sedation by propofol and remifentanil TCI has a low incidence of catastrophic and severe events.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Barends CRM, Driesens MK, van Amsterdam K, et al. Moderate-to-Deep Sedation Using Target-Controlled Infusions of Propofol and Remifentanil: Adverse Events and Risk Factors: A Retrospective Cohort Study of 2937 Procedures. Anesth Analg. 2020. PMID: 32925338. doi:10.1213/ANE.0000000000004593

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。